Endovascular Engineering (E2) has secured US$42 million in an oversubscribed Series B financing to advance its next-generation clot removal technology platform for venous thromboembolism (VTE), a press release reports.
E2 shares that the round was co-led by 415 Capital and S3 Ventures, with participation of Panakès Partners, M&L Healthcare, and strong support from founding investor Santé Ventures. Two global strategic investors made substantial commitments alongside Cordis, which continues its strategic partnership with E2.
“The capital injection accelerates E2’s mission to transform VTE treatment, placing an initial focus on advancing novel solutions for addressing pulmonary embolism (PE),” a press release reads. “As the company approaches completing enrolment in its ENGULF pivotal trial to evaluate the Hēlo PE thrombectomy system, the additional capital strengthens E2’s position to address critical unmet needs in interventional medicine while pursuing a new standard of care for both patients and physicians.”
E2’s chief executive officer Dan Rose said: “This financing represents more than capital—it validates our technology platform and positions us to revolutionise PE treatment. With strong support from sophisticated healthcare investors like 415 Capital and S3 Ventures, we are well-positioned to establish the Hēlo PE system as the gold standard in mechanical thrombectomy for pulmonary embolism.”
“E2 is developing a best-in-class therapy for PE, the third leading cause of cardiovascular death. Its differentiated technology and vision align closely with our mission to advance novel cardiovascular therapies, and we are proud to support E2 as it advances the Hēlo PE thrombectomy platform towards FDA [US Food and Drug Administration] approval,” said Ruben Osnabrugge, partner at 415 Capital.
Brian R Smith, managing director at S3 Ventures, said: “We are truly impressed by E2’s next-generation platform technology for VTE and see this as a solution to dramatically scale the mechanical thrombectomy market and improve the lives of patients.”
The company also announced the appointment of Ruben Osnabrugge of 415 Capital and Brian R Smith of S3 Ventures to its board of directors.
